Cyclophosphamide and mercaptoethane sulfonate therapy for minimal lesion glomerulonephritis  by Kleta, Robert
Letters to the Editor2312
Table 1. Characteristics of subjects and BIA data from different studies in hemodialysis
Study Ikizler [1] Chertow [2] Piccoli [3]
Whole population, N 73 3009 1367
Race-ethnicity
Caucasian 27% 45% 100%
African American 73% 47%
Other 7.7%
Gender 53% Men 53% Men 58% Men
Age years 56 61 60
Height cm — 167 164
Stable, N 5 1116 Unstable, N 5 251HD hemodynamics
Timing of BIA Post-HD Pre-HD Pre-HD Post-HD Pre-HD Post-HD
BMI kg/m2 — 27 24 24 24 24
R Ohm — 498 517 608 543 633
Xc Ohm 49 41 45 61 41 54
Phase angle, 8 — 4.8 5.0 5.7 4.4 4.9
Men, N 39 1589 680 680 118 118
BMI, kg/m2 — 26 24 24 24 24
R Ohm — 460 493 578 505 588
Xc Ohm — 41 44 60 40 51
Phase angle, 8 — 5.1 5.1 5.9 4.5 5.0
Women, N 34 1420 436 436 133 133
BMI kg/m2 — 29 24 24 24 24
R Ohm — 531 554 656 577 673
Xc Ohm — 41 46 62 43 57
Phase angle, 8 — 4.5 4.7 5.4 4.3 4.8
African American, N 53 1411 0 0 0 0
BMI kg/m2 — 27
R Ohm — 491
Xc Ohm — 44
Phase angle, 8 — 5.2
Other, N 20 1598 1116 1116 251 251
BMI kg/m2 — 28 24 24 24 24
R Ohm — 499 517 608 543 633
Xc Ohm — 38 45 61 41 54
Phase angle, 8 — 4.4 5.0 5.7 4.4 4.9
Abbreviations are: BIA, bioelectrical impedance analysis; N, number of subjects; R, resistance; Xc, reactance; BMI, body mass index; HD, hemodialysis.
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Shouldn’t cyclophosphamide be administered always don’t add some MESNA to cyclophosphamide even as
nephrologists? There is some evidence.together with mercaptoethane sulfonate (MESNA)?
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